http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H10500394-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-044 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-044 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H9-06 |
| filingDate | 1995-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1998-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H10500394-A |
| titleOfInvention | Polycyclic lactam derivatives for sensitizing multidrug resistant cells to antitumor agents |
| abstract | (57) [Summary] 1. Staurosporine derivative of formula I Wherein R 1 is formyl, an aliphatic hydrocarbon group having up to 29 carbon atoms, unsubstituted or substituted by aryl, or an aryl group, and R 2 is a C 1 -C 5 alkyl. Alicyclic, carbocyclic, carbocyclic-aliphatic, heterocyclic or heterocyclic-aliphatic radicals having up to 29 carbon atoms each, but excluding up to 20 carbon atoms and up to 9 heteroatoms Or an acyl having up to 30 carbon atoms other than benzoyl, benzyloxycarbonyl, lower alkanoyl or an α-aminoacyl having a free or protected amino group, respectively. And R 3 is hydrogen, hydroxy, lower alkoxy or oxo) or a salt of such a compound of formula I with at least one salt-forming group. These derivatives can be used to avoid or eliminate multiple drug resistance to anti-tumor agents, such as vinblastine or adriamycin. |
| priorityDate | 1994-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 277.